Many inhibitors have already been proposed to target tyrosine kinases-epidermal growth factor receptor (TKI-EGFR), inhibitors of ALK, ROS1, BRAF, NTRK, and immunotherapy using monoclonal antibodies, mainly against the programmed cell death one receptor (PD-1, programmed cell death 1) or its ligand (PD-L1, programmed cell death ligand 1) to improve the therapeutic efficacy of NSCLC [241]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.